On February 9, 2023 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, reported the presentation of additional results from its completed Phase 3 LIGHTHOUSE trial of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer, at the upcoming ASCO (Free ASCO Whitepaper) GU 2023 Genitourinary Cancers Symposium (ASCO GU) (Press release, Blue Earth Diagnostics, FEB 9, 2023, View Source [SID1234627025]). The conference will be held in San Francisco, Calif., from February 16 to 18, 2023. 18F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent. The now completed LIGHTHOUSE Phase 3 clinical trial (NCT04186819) was a prospective, Phase 3, multi-center, single-arm, imaging study conducted in the United States and Europe to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 Positron Emission Tomography (PET) in men with newly diagnosed prostate cancer. Currently, 18F-rhPSMA-7.3 is investigational and has not received regulatory approval.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are listed below.
Date:
Thursday, February 16, 2023
Track:
Prostate Cancer – Advanced Prostate Cancer – Localized
Sub-Track:
Diagnostics and Imaging
Title:
Detection of true positive M1 lesions by 18F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.
Presenter:
Brian F. Chapin, MD, Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, on behalf of Bridget F. Koontz, MD, Duke University Medical Center, and the LIGHTHOUSE Study Group.
Session:
Poster Session A: Prostate Cancer
Abstract:
315
Location:
Poster board K15
Session Times:
11:30 AM – 1:00 PM PT; 5:45 – 6:45 PM PT
Blue Earth Diagnostics invites participants at the ASCO (Free ASCO Whitepaper) 2023 Genitourinary Cancers Symposium to attend the presentation above. Participants onsite are also invited to visit Blue Earth Diagnostics’ Medical Affairs booth (#21). For full session details and scientific presentation listings, please see the ASCO (Free ASCO Whitepaper) GU online program here.
About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)
rhPSMA compounds consist of a radiohybrid ("rh") Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells and they may be radiolabeled with 18F for PET imaging, or with isotopes such as 177Lu or 225Ac for therapeutic use – creating a true theranostic technology. The radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA imaging technology from Scintomics GmbH in 2018, followed by acquisition of exclusive rights to therapeutic applications in 2020. Blue Earth Diagnostics has two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: ("SPOTLIGHT," NCT04186845), in men with recurrent disease and ("LIGHTHOUSE," NCT04186819), in men with newly diagnosed prostate cancer. rhPSMA compounds are investigational and have not received regulatory approval.